DaVita HealthCare Partners vs Alignment Healthcare LLC: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

DaVita HealthCare Partners Inc (DVA)

Q3 202617 Jun – 7 Aug 2026

▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.
This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.
Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.
Guidance raise and buybacks are direct positive catalysts for the stock.
Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.
This explains the negative price reaction despite headline beats.
Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.
This is the key reason for the sharp negative price move after earnings.

July 202617 Jun – 7 Aug 2026

▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.
This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.
Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.
Guidance raise and buybacks are direct positive catalysts for the stock.
Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.
This explains the negative price reaction despite headline beats.
Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.
This is the key reason for the sharp negative price move after earnings.

Latest17 Jun – 7 Aug 2026

▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.
This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.
Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.
Guidance raise and buybacks are direct positive catalysts for the stock.
Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.
This explains the negative price reaction despite headline beats.
Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.
This is the key reason for the sharp negative price move after earnings.

Alignment Healthcare LLC (ALHC)

Q3 20262 Jul – 31 Jul 2026

▲2▼1

Whistleblower Lawsuit and Investigations Hit ALHC Despite Strong Results

Whistleblower lawsuit and securities investigations A former executive sued on July 8, claiming Alignment misclassified expenses to inflate profits and pay. The stock fell 16.7%, and multiple law firms launched investigations, raising legal costs and uncertainty.
This is the main new negative event that drove the stock down in July.
Strong Q1 and Q2 revenue growth Alignment reported Q1 revenue up 33.3% to $1.24 billion and Q2 revenue up 31.6% to $1.34 billion, both beating estimates. Membership grew to 294,100, and the medical benefits ratio improved.
These results show underlying business strength that supports the stock despite legal issues.
Higher 2026 Star Ratings Improved Star Ratings for 2026 could lead to higher future reimbursement from Medicare, boosting revenue and profitability. This is a positive fundamental development for the company.
Star Ratings are a key driver of future Medicare payments and thus a positive catalyst.

July 20262 Jul – 31 Jul 2026

▲2▼1

Whistleblower Lawsuit and Investigations Hit ALHC Despite Strong Results

Whistleblower lawsuit and securities investigations A former executive sued on July 8, claiming Alignment misclassified expenses to inflate profits and pay. The stock fell 16.7%, and multiple law firms launched investigations, raising legal costs and uncertainty.
This is the main new negative event that drove the stock down in July.
Strong Q1 and Q2 revenue growth Alignment reported Q1 revenue up 33.3% to $1.24 billion and Q2 revenue up 31.6% to $1.34 billion, both beating estimates. Membership grew to 294,100, and the medical benefits ratio improved.
These results show underlying business strength that supports the stock despite legal issues.
Higher 2026 Star Ratings Improved Star Ratings for 2026 could lead to higher future reimbursement from Medicare, boosting revenue and profitability. This is a positive fundamental development for the company.
Star Ratings are a key driver of future Medicare payments and thus a positive catalyst.

Latest27 Jul – 31 Jul 2026

▲1▼1

Legal Cloud Grows as Strong Q2 Earnings Beat Estimates

More law firms join accounting investigation Kaplan Fox, Holzer & Holzer, Hagens Berman, Lowey Dannenberg, and Frank R. Cruz all launched or continued investigations into Alignment's accounting. This keeps the whistleblower scandal alive, raising legal costs and uncertainty that weigh on the stock.
This is the main new negative force this period, extending the legal overhang from earlier reports.
Q2 revenue and profit beat expectations Alignment reported Q2 revenue of $1.34 billion, up 31.6%, and earnings per share of $0.17, both above analyst estimates. Membership grew to 294,100, and the medical benefits ratio improved, showing the core business is strong.
This is the only new positive fundamental news this period, providing a counterweight to the legal issues.

2 Jul – 21 Jul 2026

▼2▲1

Whistleblower Accounting Claims Trigger Investigations, Stock Plunge

Strong Q1 Earnings and Membership Growth Alignment Healthcare reported Q1 revenue of $1.24 billion, up 33.3% year-over-year, with earnings per share beating expectations. Membership grew by 48,500 to 284,800, and analysts raised full-year earnings estimates. Higher Star Ratings across all plans for 2026 could boost future reimbursement. This positive news initially pushed the stock up 10.7%.
This is a key positive driver that contrasts with the negative news later in the period, providing a balanced view.
Whistleblower Lawsuit Alleges Financial Manipulation On July 8, a former executive filed a whistleblower lawsuit alleging Alignment misclassified operating expenses as capital expenditures to inflate adjusted EBITDA and boost stock price and executive pay. The company denies the claims and vows to defend itself. The stock fell 16.7% on the news, its worst drop since February 2024.
This is the primary negative event that caused a sharp stock decline and triggered multiple investigations.
Multiple Law Firms Launch Investigations Following the whistleblower lawsuit, law firms Block & Leviton, Hagens Berman, Kaplan Fox, and Bragar Eagel & Squire announced investigations into Alignment for potential securities law violations. These investigations could lead to lawsuits and further pressure the stock as legal costs and uncertainty rise.
These investigations amplify the negative impact and keep the issue in the spotlight, affecting investor sentiment.